SequelSEC

Jade Biosciences, Inc. JBIO

Pharmaceutical Preparations · CIK 0001798749 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$58.92M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Jade Biosciences, Inc. (JBIO) reported net income of -$55.76M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Jade Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Jade Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$58.92MUnavailable-$34.98M-$27.40MUnavailableUnavailable-$6.40MUnavailableUnavailableUnavailable
Net income-$55.76MUnavailable-$31.93M-$25.18MUnavailableUnavailable-$5.43MUnavailableUnavailableUnavailable
Research & development$50.06MUnavailable$28.54M$22.01MUnavailableUnavailable$1.53MUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 61.05MUnavailableUnavailableshares 39.58MUnavailableUnavailableUnavailableshares 3.16MUnavailableUnavailable
Pretax income-$55.75MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$15.00KUnavailable$58.00K$0UnavailableUnavailableUnavailable$0UnavailableUnavailable
Diluted EPS$-0.76UnavailableUnavailable$-0.48UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$8.85MUnavailable$6.44M$5.39MUnavailableUnavailable$4.87MUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Jade Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$107.25MUnavailable$88.44M$50.11MUnavailableUnavailable$69.39M$31.12MUnavailableUnavailable
Total assets$472.11MUnavailable$349.78M$202.45MUnavailableUnavailable$72.80M$90.96MUnavailableUnavailable
Current assets$471.25MUnavailable$348.82M$201.36MUnavailableUnavailable$69.65M$90.60MUnavailableUnavailable
Total liabilities$32.20MUnavailable$17.26M$23.10MUnavailableUnavailable$119.60M$10.47MUnavailableUnavailable
Current liabilities$31.57MUnavailable$16.54M$22.36MUnavailableUnavailable$12.00M$10.32MUnavailableUnavailable
Total equity incl. NCI$439.92MUnavailable$332.52M$179.35MUnavailableUnavailable-$46.80M-$16.86MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$6.58MUnavailable$2.15M$1.35MUnavailableUnavailable$1.29M$908.00KUnavailableUnavailable

Cash flow

Jade Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$43.66MUnavailable-$33.65M-$22.12MUnavailableUnavailable-$11.05M-$6.80MUnavailableUnavailable
Capital expendituresUnavailableUnavailable$3.00K$57.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$97.63MUnavailable-$98.16M-$148.71MUnavailableUnavailable$13.13M$0UnavailableUnavailable
Financing cash flow$193.52MUnavailable$170.16M$0UnavailableUnavailable$554.00K$94.77MUnavailableUnavailable
Net change in cash$52.16MUnavailable$38.33M-$170.84MUnavailableUnavailable$2.64M$87.97MUnavailableUnavailable
Stock-based compensation$13.61MUnavailable$9.40M$4.30MUnavailableUnavailable$1.24M$27.00KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Jade Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailable-$33.65M-$22.18MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio14.93xUnavailable21.09x9.01xUnavailableUnavailable5.81x8.78xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JBIO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-06View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-04-25View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

15 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.